Kathryn O'Driscoll
Net Worth

Last updated:

What is Kathryn O'Driscoll net worth?

The estimated net worth of Ms. Kathryn O'Driscoll is at least $2,556,642 as of 15 Mar 2021. She owns shares worth $70,542 as insider and has received compensation worth at least $2,486,100 in Zymeworks Inc..

What is the salary of Kathryn O'Driscoll?

Ms. Kathryn O'Driscoll salary is $497,220 per year as Chief People Officer in Zymeworks Inc..

How old is Kathryn O'Driscoll?

Ms. Kathryn O'Driscoll is 61 years old, born in 1964.

What stocks does Kathryn O'Driscoll currently own?

As insider, Ms. Kathryn O'Driscoll owns shares in one company:

Company Title Shares Price per share Total value
Zymeworks Inc. (ZYME) Chief People Officer 5,003 $14.1 $70,542

What does Zymeworks Inc. do?

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME logo
ZYME
Zymeworks Inc.
$14.1

Kathryn O'Driscoll insider trading

Zymeworks Inc.

Ms. Kathryn O'Driscoll has made 2 insider trades between 2020-2021, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 2,920 units of ZYME stock on 18 Nov 2020. As of 15 Mar 2021 she still owns at least 5,003 units of ZYME stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Shares 837 $34.24 $28,659
Sale
Common Shares 786 N/A N/A
Option
Stock Option (Right to Buy) 837 $34.24 $28,659
Sale
Common Shares 568 N/A N/A
Option
Common Shares 1,354 N/A N/A
Option
Restricted Stock Unit 1,354 $34.82 $47,146
Option
Stock Option (Right to Buy) 2,083 N/A N/A
Option
Common Shares 2,083 $34.24 $71,322
Option
Stock Option (Right to Buy) 2,920 N/A N/A
Option
Common Shares 2,920 N/A N/A

Zymeworks key executives

Zymeworks Inc. executives and other stock owners filed with the SEC:

  • Dr. Ali Tehrani (53) Co-Founder, Pres, Chief Executive Officer & Director
  • Dr. Anthony J. Polverino Ph.D. (62) Chief Scientific Officer & Executive Vice President of Early Devel.
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA (53) Executive Vice President of Bus. Operations & Chief Financial Officer
  • Ms. Kathryn O'Driscoll (61) Chief People Officer